ACERTA PHARMA - Key Persons

Job Titles:

• AstraZeneca in 2020 As the Senior Vice President, Global Head
• Senior Vice President, Global Head of Haematology ( Early and Late Stage ) Oncology R & D, New York, United States

Anas joined AstraZeneca in 2020 as the Senior Vice President, Global Head of Haematology (Early and Late Stage). As a trained clinician-scientist, Anas has spent more than 25 years caring for patients with lymphoma. Prior to joining AstraZeneca, Anas was at Memorial Sloan Kettering Cancer Center (MSKCC) where he served as the Chief of the Lymphoma Service, in addition to leading a laboratory focused on drug development for patients with lymphoid malignancies. Prior to MSKCC, Anas worked for 20 years at University of Texas MD Anderson Cancer Center (MDACC) where he directed clinical and translational research in the Department of Lymphoma and Myeloma.

Job Titles:

• Vice President, Head of Discovery and Target Biology, Cambridge, United Kingdom

Jude joined AstraZeneca in September 2022 as Vice President, Head of Discovery and Target Biology. Prior to joining AstraZeneca, Jude worked as a Professor of Personalised Cancer Medicine at the Barts Cancer Institute, Queen Mary University of London where he led the Centre for Cancer Genomics and Computational Biology. His research focused on the genetic and epigenetic changes responsible for the development and progression of leukaemia and lymphomas. He received his Bachelor of Arts in Genetics from Trinity College Dublin before completing his Doctor of Philosophy at University College London.

Job Titles:

• Country President AstraZeneca Netherlands / Den Haag, Netherlands
• Director of Oncology for the Dutch AstraZeneca

Martijn joined AstraZeneca in 2016 as director of oncology for the Dutch AstraZeneca branch. He moved to a European role in 2019, being responsible for improving access to oncologic treatment, making treatment options accessible to hundreds of thousands of people with cancer. Martijn rejoined AstraZeneca Netherlands as Country President in March 2022.

Job Titles:

• R & D Finance Director - Haematology
• R & D Finance Director Haematology, Gaithersburg, United States

Mauricio has more than 15 years of professional experience in several business and financial leadership functions. Mauricio received his Bachelor of Finance in 1999 from the Universidad Panamericana and MBA from Universidad Anahuac in 2004 in Mexico City. Mauricio joined AstraZeneca as FP&A Manager in Mexico and gained significant commercial experience in roles in the United Kingdom and Germany. He is known for his passion to be a strategic and tactical business partner and building high-performance teams. Mauricio served as the CFO for CAMCAR MAC (Central America, Caribbean and Mid Andean Countries) based in Costa Rica where his responsibilities extended well beyond Finance. He relocated to Gaithersburg, MD, USA to join the GPPS area as the Therapeutic Area Finance Director for Infection, Neuroscience and Autoimmunity (INA) continuing to deliver additional value to mature brands and supported diverse initiatives for the pipeline portfolio, including TA strategy and portfolio prioritization. Prior to joining AstraZeneca, Mauricio worked for companies such as General Electric, British Petroleum and the Mexican Stock Exchange in the areas of Planning and Financial Performance. During his free time Mauricio enjoys traveling, photography and playing soccer with his two boys.

Job Titles:

• CEO & Vice President Research Europe, Netherlands

Nico joined Acerta Pharma in January 2018 as Vice President Research Europe & Site Head of Acerta's R&D site in The Netherlands. Nico has over 25 years of experience in pharmaceutical industry, and held executive positions in business development & licensing, R&D portfolio management, strategy, merger & acquisition research, and R&D at Merck & Co, Schering-Plough, and Organon. Furthermore, as business lead, he played a pivotal role in setting up fundraising activities for, several biotech start-ups and spin-out companies. In several of these companies, he served as interim CEO, or member of the advisory board. Nico received an MSc degree in Chemistry, and a PhD in immunology/cancer research from the Free University Amsterdam & Netherlands Cancer Institute. Furthermore, he holds a Master's degree in Business Administration (MBA) and is a Certified Licensing Professional (CLP™).

Job Titles:

• AstraZeneca in 2020 As Global Franchise Head
• Global Franchise Head Immuno Oncology ( Early and Late Stage ) Neuhofstrasse, Switzerland
• Global Franchise Head Immuno Oncology / Baar, Switzerland

Niko joined AstraZeneca in 2020 as Global Franchise Head within the global Oncology Business Unit, initially for Haematology and since 2021 for Immuno Oncology. Prior to joining AstraZeneca he spent nearly 15 years at Roche Pharma in life cycle management roles on global and local level, most recently as SVP Global Medical Affairs. Niko is a Medical Oncologist and Hematologist by training. Besides his significant clinical tenure caring for cancer patients he served as a clinical investigator and collaborative group member in a broad range of registrational and scientific programs. During his post doc fellowship at Harvard medical school Niko focused his research on T cell mobilization and molecular patterns of cell migration. Niko is an active member of ASH, ESMO, ASCO, AACR and diverse national scientific and research groups. He lives and operates from Switzerland.

Job Titles:

• Executive Director Clinical Operations Haematology / Cambridge, United Kingdom
• Head of Hematology R & D Clinical Operations, Cambridge, United Kingdom

Sally has over 20 years of Oncology Clinical Operations leadership experience, spanning Phase I-IV. Sally joined AstraZeneca in 2000 as a Global Study Leader, having previously worked with Eli Lilly, where she was responsible for delivering and optimizing clinical trial programs. During her time at AstraZeneca, Sally has held various leadership roles of increasing responsibility, most recently serving as the Executive Director of GI and Head/Neck in Clinical Operations, where she oversaw the delivery of portfolio studies and led the program management teams. For over two years Sally led the Design, Label and Submission Value Chain in Operational Excellence delivering improvement initiatives including the Global Product Team (GPT) operating model and new Development Review Committee (DRC) format across all therapeutic areas. As part of this role Sally also played a lead role in the integration of Acerta into AstraZeneca, the design of the original Haematology organization and governance structure across AstraZeneca